他唑巴坦钠 | 89785-84-2

• 物质功能分类: 原料药 - 抗生素类药物 - β-内酰胺酶抑制剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 他唑巴坦钠
• 中文别名: 泰唑巴坦钠；[2S-(2a,3b,5a)]-3-甲基-7-氧代-3-(1H-1,2,3-三氮唑-1-基甲基)-4-硫代-1-氮杂双环[3,2,0]庚烷-2-羧酸钠4,4-二氧化物；[2S-(2a,3b,5a)]-3-甲基-7-氧代-3-(1H-1,2,3-三氮唑-1-基甲基)-4-硫代-1-氮杂双环[3,2,0]庚烷-2-羧酸钠 4,4-二氧化物；三唑巴坦钠
• CAS: 89785-84-2
• 化学式: C10H12N4NaO5S
• 分子量: 323.28
• InChiKey: ZUNWFYFXHGWFRA-QVUDESDKSA-N

物化性质

• 熔点：
  140-147°C
• 沸点：
  77℃
• 闪点：
  >110°(230°F)
• 溶解度：
  H2O：50 mg/mL，澄清，无色

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2934999090
• RTECS号：
  XI0191500

制备方法与用途

生物活性

Tazobactam钠是一种β-内酰胺酶抑制剂类抗生素。当Ceftolozane与Tazobactam联合应用时，可显著提高头孢噻嗪对多种产ESBL肠杆菌科和部分铜绿假单胞菌的抗菌活性。

用途

不可逆竞争性β-内酰胺酶抑制剂。

文献信息

• SUBSTITUTED CLAVULANIC ACID
  申请人：Bulusu Atchyuta Rama Chandra Murty

  公开号：US20120232047A1

  公开（公告）日：2012-09-13

  The present invention relates to compounds of formula I and to compounds of formula II wherein the substituents have various meanings. These compounds are useful as beta lactamase inhibitors.

  本发明涉及式I化合物和式II化合物，其中取代基具有各种含义。这些化合物作为β-内酰胺酶抑制剂是有用的。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS
  申请人：Yu Chongxi

  公开号：US20100040548A1

  公开（公告）日：2010-02-18

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  该发明提供了一种新型高渗透性复合物（HPC）或高渗透性前药（HPP）的组合物，包括抗微生物和抗微生物相关化合物，这些化合物能够以高渗透效率穿越生物屏障。HPP能够在穿越生物屏障后转化为母药活性药物或药物代谢物，从而可以治疗母药或代谢物所能治疗的疾病。此外，HPP能够到达母药可能无法进入或在目标区域获得足够浓度的区域，从而提供新的治疗方法。HPP可以通过各种给药途径向受试者施用，例如，局部给药到病情作用部位以高浓度，或者系统给药到生物体内并以更快速度进入全身循环。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Hybrid molecules QA, wherein Q is an aminoquinoline and a is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent
  申请人：Sanchez Muriel

  公开号：US20060025327A1

  公开（公告）日：2006-02-02

  Aminoquinoline-antibiotic hybrid compounds in the form of hybrid molecules QA, wherein Q is an aminoquinoline and A is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent. This compound is defined by the general formula (I): Q-(Y 1 ) p —(U) p′ —(Y 2 ) p″ -A  (I) in which Q represents an aminoquinoline, (Y 1 ) p —(U) p′ —(Y 2 ) p″ — is an optional spacer arm and A is an antibiotic, one of its derivatives or precursors, or a resistance enzyme inhibitor. The invention unexpectedly enables the activity of the antibiotic to be improved.

  氨基喹啉-抗生素混合物化合物以混合分子QA的形式存在，其中Q是氨基喹啉，A是抗生素或耐药酶抑制剂，它们的合成及用途作为抗菌剂。该化合物由通用公式(I)定义：Q-(Y1)p—(U)p′—(Y2)p″-A  (I)其中Q代表氨基喹啉，(Y1)p—(U)p′—(Y2)p″—为可选的间隔臂，A是抗生素、其衍生物或前体之一，或耐药酶抑制剂。该发明意外地能够改善抗生素的活性。